
Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16
Published: March 5, 2025
Non-chemotherapy drug-induced agranulocytosis (NCDIA) is a serious adverse reaction that significantly increases the risk of life-threatening infections. Although association between certain non-chemotherapy drugs and has been documented, comprehensive analysis using large-scale pharmacovigilance database lacking. This study aimed to systematically identify characterize NCDIA by analyzing event reports from FAERS database. We conducted retrospective spanning 2004 2024 Q1. Drugs were classified Anatomical Therapeutic Chemical (ATC) classification system, with chemotherapy agents (ATC code L01) excluded. The Reporting Odds Ratio (ROR) method was employed detect potential signals. Positive signals defined as cases at least three lower 95% confidence interval (CI) ROR greater than one. Time-to-event also performed examine onset patterns across different demographic groups drugs. A total 10,913 identified Disproportionality revealed significant for 166 related agranulocytosis, which into categories: known (n = 111), possible 25), new risks 30). system enables us risks, those might pose risk, warranting further investigation. Demographic females, children (<18 years), elderly (≥65 years) experienced earlier agranulocytosis. Drug-specific timing provided evidence optimizing monitoring protocols. Notably, NCDIA-associated mortality rates showed decrease 11.91% (2004-2010) 7.28% (2021-2024) (P < 0.001). not only confirmed previously associations but novel detailed provide valuable insights clinical monitoring. findings in specific populations declining trends have important implications developing targeted surveillance strategies improving patient safety management.
Language: Английский